Michael Kelly

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

NeoGenomics Laboratories, Inc. operates as a cancer diagnostics and pharma services company. It serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with diagnostic, prognostic and predictive testing. The company was founded in 2002 and is headquartered in Fort Myers, FL.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.